Trial Profile
Phase II trial of apatinib in the treatment of metastatic penile cancer
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 11 Mar 2019
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Penile cancer; Squamous cell cancer
- Focus Therapeutic Use
- 16 Feb 2019 9 patients were enrolled from October 2016 to May 2018, and eight patients were eligible for efficacy analysis as per trial design presented at the 2019 Genitourinary Cancers Symposium
- 16 Feb 2019 Trial design presented at the 2019 Genitourinary Cancers Symposium
- 13 May 2016 New trial record